ACTR-19. REPORT ON THE COMBINATION OF AXITINIB AND TUMOR TREATING FIELDS (TTFIELDS) IN THREE PATIENTS WITH RECURRENT GLIOBLASTOMA

OBJECTIVE: Tumor Treating Fields (TTFields) significantly improved survival of newly diagnosed glioblastoma (ndGBM) patients in the EF-14 trial. Axitinib is an orally available tyrosine kinase inhibitor which is approved for the treatment of metastatic renal cell carcinoma. It has a high affinity an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Schulz, Ellina, Kessler, Almuth F, Weiland, Judith, Linsenmann, Thomas, Ernestus, Ralf-Ingo, Hagemann, Carsten, Löhr, Mario
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Adult Clinical Trials - Non-Immunologic
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847705/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.062
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky